10:48 AM EDT, 08/06/2024 (MT Newswires) -- Merck ( MRK ) and Daiichi Sankyo said Tuesday they have expanded their global partnership to include Merck's ( MRK ) investigational drug MK-6070, a T-cell engager targeting delta-like ligand 3, a protein associated with small cell lung cancer and neuroendocrine tumors.

Under the expanded agreement, the companies will jointly develop and commercialize MK-6070 worldwide, except in Japan where Merck ( MRK ) will maintain exclusive rights, the company said, adding that Merck ( MRK ) will also be responsible for the drug's manufacturing and supply.

MK-6070 is currently undergoing a phase 1/2 clinical trial and both companies plan to test the drug in combination with ifinatamab deruxtecan, or I-DXd for certain patients with small cell lung cancer, among other potential combinations, according to a joint statement.

Price: 112.95, Change: +0.64, Percent Change: +0.57